Agenus has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Correspondingly, Will AGEN stock go up? The Wall Street analyst predicted that AGENUS’s share price could reach $14.00 by Mar 2, 2023. The average AGENUS stock price prediction forecasts a potential upside of 498.29% from the current AGEN share price of $2.34.
Why is AGEN dropping? Shares of Agenus ( AGEN 5.09% ) dropped more than 32% this morning after the company gave investors bad news regarding its experimental cancer immunotherapy balstilimab. The company has withdrawn the Biologics License Application (BLA) that the Food and Drug Administration (FDA) began reviewing earlier this year.
Furthermore, Why is agenus stock up?
Why Agenus Stock Is Crushing It Today
In response to the impressive clinical progress of Agenus’ anti-cancer checkpoint inhibitor platform, Wainwright raised its 12-month price target on the biotech’s shares to $14 ahead of the opening bell this morning.
What type of stock is AGEN?
Common Stock (AGEN)
What kind of company is AGEN? Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer.
When did AGEN go public? The company has pioneered immunotherapies, including heat shock protein-based cancer vaccines, a program that has developed into its Prophage Series of personalized anti-cancer vaccines. Antigenics became a public company in February 2000 on the NASDAQ exchange with the ticker symbol AGEN.
What drugs does agenus make? Agenus has programs targeting the checkpoint modulators GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company is expanding that portfolio by using a proprietary process to generate fully human therapeutic antibody drug candidates.
How many employees does agenus?
Compare AGEN With Other Stocks
| Agenus Annual Number of Employees | |
|---|---|
| 2020 | 359 |
| 2019 | 328 |
| 2018 | 294 |
| 2017 | 255 |
Is agenus a good company? Agenus Reviews FAQs
Is Agenus a good company to work for? Agenus has an overall rating of 3.3 out of 5, based on over 55 reviews left anonymously by employees. 53% of employees would recommend working at Agenus to a friend and 52% have a positive outlook for the business.
Does agenus stock pay dividends?
AGENUS (NASDAQ: AGEN) does not pay a dividend.
Who owns agenus? Top 10 Owners of Agenus Inc
| Stockholder | Stake | Total value ($) |
|---|---|---|
| The Vanguard Group, Inc. | 6.63% | 41,948,983 |
| BlackRock Fund Advisors | 5.63% | 35,636,241 |
| Oracle Investment Management, Inc… | 3.54% | 22,401,085 |
| Invus Public Equities Advisors LL… | 2.53% | 15,990,000 |
What is AGEN1181?
AGEN1181 is a multipurpose, second-generation “Fc-engineered” anti-CTLA-4 antibody with enhanced tumor fighting abilities, designed to generate responses in a larger number of patients and improve immunogenicity.
Is Spectrum Pharmaceuticals a good investment?
Is SPECTRUM PHARMACEUTICALS Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: SPPI) stock is to Strong Buy SPPI stock.
Where can I buy agenus stock? Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. Stash allows you to purchase smaller pieces of investments, called fractional shares, rather than having to pay the full price for a whole share. , you can buy Agenus Inc. stock in any dollar amount, or any other fund or stock you know on Stash.
Is Spectrum Pharmaceuticals a good company? Is Spectrum Pharmaceuticals a good company to work for? Spectrum Pharmaceuticals has an overall rating of 2.9 out of 5, based on over 46 reviews left anonymously by employees. 44% of employees would recommend working at Spectrum Pharmaceuticals to a friend and 35% have a positive outlook for the business.
Will Spectrum Pharmaceuticals go up?
The 5 analysts offering 12-month price forecasts for Spectrum Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +252.42% increase from the last price of 1.14.
Why is Spectrum Pharmaceuticals down? Why Spectrum Pharmaceuticals Stock Is Crashing Today
The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving cancer drugs that decrease bone marrow activity.
Will Rolontis get approved?
Hanmi Pharm expects FDA nod for 2 drugs, to begin mRNA vaccine clinical trials. South Korea’s Hanmi Pharmaceutical is expected to receive FDA approval for « Rolontis », a treatment for neutropenia and “Poziotinib”, an anticancer drug this year.
Did Sppi get FDA approval? –(BUSINESS WIRE)– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of Beleodaq™ for the …
Did SPPI get FDA approval?
–(BUSINESS WIRE)– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of Beleodaq™ for the …
Is Rolontis FDA approved? It is a long-acting biologic medicine to treat or prevent neutropenia in cancer patients receiving chemotherapy. Rolontis obtained the Ministry of Food and Drug Safety’s approval in March, becoming Hanmi’s first biologic drug and the nation’s 33rd novel drug.
Will Sppi get FDA approval? –(BUSINESS WIRE)–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that its New Drug Application (NDA) for poziotinib has been accepted for review by the U.S. Food and Drug Administration (FDA).
What is Rolontis?
ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs.
